Drugs of Abuse, Dopamine, and HIV-Associated Neurocognitive Disorders/HIV-Associated Dementia

  title={Drugs of Abuse, Dopamine, and HIV-Associated Neurocognitive Disorders/HIV-Associated Dementia},
  author={Vishnudutt Purohit and Rao S. Rapaka and David Shurtleff},
  journal={Molecular Neurobiology},
Although the incidence of HIV-associated dementia (HAD) has declined, HIV-associated neurocognitive disorders (HAND) remain a significant health problem despite use of highly active antiretroviral therapy. In addition, the incidence and/or severity of HAND/HAD are increased with concomitant use of drugs of abuse, such as cocaine, marijuana, and methamphetamine. Furthermore, exposure to most drugs of abuse increases brain levels of dopamine, which has been implicated in the pathogenesis of HIV… 

HIV-Related Neurocognitive Disorders and Drugs of Abuse: Mired in Confound, Surrounded by Risk

This review examines the literature available to try to elucidate the mechanisms of neurocognitive disorders in the HIV-infected individuals who have used drugs of abuse and considers for prevention.

HIV-Associated Neurocognitive Disorder: The Interaction Between HIV-1 and Dopamine Transporter Structure

Details of the computational modeling studies on mechanisms and structures of human dopamine transporter (hDAT) and its interaction with HIV-1 trans activator of transcription (Tat) are discussed.

NeuroHIV and use of addictive substances.

The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders

The latest findings of the effects of Tat and MA in HAND are reviewed and a few promising potential therapeutic developments are discussed.

Drug Induced Increases in CNS Dopamine Alter Monocyte, Macrophage and T Cell Functions: Implications for HAND

Characterizing the effects of dopamine on monocytes and macrophages is important for understanding the mechanisms that mediate the development of HAND in drug abusers.

HIV Infection and Neurocognitive Disorders in the Context of Chronic Drug Abuse: Evidence for Divergent Findings Dependent upon Prior Drug History

How the fronto-striatal circuit adapts to drug use, HIV-1 infection, and both together is explored, emphasizing proper methods and providing future directions to develop treatments for pathologies disrupting goal-directed behaviors and improve clinical outcomes for affected patients.

The role of human dopamine transporter in NeuroAIDS☆

Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways

How HIV can predispose infected individuals to depression by several interrelated mechanisms is discussed, including inducing chronic elevation of cytokines through activation of microglia and astrocytes; decreasing monoaminergic function; inducing neurotoxicity, especially in dopaminergic neurons; and reducing brain-derived neurotrophic factor.

Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms.

Previous studies on the mechanism(s) underlying the interplay of cocaine and HIV as it relates to the CNS are summarized.



Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse.

A common mechanism by which drugs of abuse enhance HIV replication in macrophages is suggested and it is indicated that the drug abuse-heightened levels of central nervous system dopamine could increase viral replication, thereby accelerating the development of HAND.

The Neuropathology of HIV/AIDS

This review focuses on the shifting pathology observed in HIV infected subjects since the introduction of HAART, discussing the clinical manifestations of these and the influence of confounding factors such as drug abuse and Hepatitis C co-infection.

Neuroimmunity, Drugs of Abuse, and neuroAIDS

Recent findings on mechanisms of actions of selected drugs reveal the possibility of protective as well as detrimental effects on the central nervous system damage induced by HIV.

Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs

A synergistic interaction between dopamine and SIV infection on microglia activation, leading to increased viral replication and production of neurotoxic substances may potentiate HIV dementia.

Decreased brain dopaminergic transporters in HIV-associated dementia patients.

The results provide the first evidence of DA terminal injury in HIV dementia patients, and suggest that decreased DAT may contribute to the pathogenesis of HIV dementia.

Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses

These findings show activation of central DA systems without development of adaptive responses at DA synapses in asymptomatic HIV infection, providing a clue to the synergism between DA medication or drugs of abuse and HIV infection to exacerbate and accelerate HIV neuropsychiatric disease, a central issue in the neurobiology of HIV.

Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains

Findings suggest widespread deficits in dopamine in different brain regions of HIV-1-infected cases, and that these deficits may be the results of HIV -1-induced neurodegeneration in the subcortical regions of human brain.

Acceleration of HIV dementia with methamphetamine and cocaine

A patient with rapidly accelerating HIV dementia accompanied by seizures and an unusual movement disorder despite highly potent antiretroviral therapy is reported, suggesting that prior drug abuse synergized with HIV to cause a domino effect on cerebral function.